Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy

Stroke

Volumn 27, Issue 7, 1996, Pages 1211-1214

  Dam, M ^a,c   Tonin, P ^b   De Boni, A ^b   Pizzolato, G ^c   Casson, S ^b   Ermani, M ^c   Freo, U ^c   Piron, L ^c   Battistin, L ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b IRCCS SAN CAMILLO HOSPITAL   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

antidepressive agents; fluoxetine maprotiline; rehabilitation; stroke outcome

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN AMINE; FLUOXETINE; MAPROTILINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DAILY LIFE ACTIVITY; DEPRESSION; DISABILITY; DRUG EFFECT; FEMALE; FUNCTIONAL ASSESSMENT; GAIT; HAMILTON SCALE; HEMIPLEGIA; HUMAN; INSOMNIA; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; STROKE; TREATMENT OUTCOME; WALKING;

EID: 0029972042     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.27.7.1211     Document Type: Article

References (45)

1. Sinyor D, Amato P, Kalouped DG, Becker R, Goldenberg M, Coopersmith H. Post-stroke depression: relationships to functional impairment, coping strategies and rehabilitation outcome. Stroke. 1986; 17:1102-1107.
2. Robinson RG, Bolduc PL, Price TR. Two year longitudinal study of post-stroke mood disorders: diagnosis and outcome at one and two years. Stroke. 1987;18:837-843.
3. Eastwood MR, Rifat SL, Nobbs H, Ruderman J. Mood disorder following cerebrovascular accident. BrJ Psychiatry. 1989;154:195-200.
4. Morris PLP, Robinson RG, Raphael B. Prevalence and course of depressive disorders in hospitalized stroke patients. Int J Psychiatry Med. 1990;20:349-364.
5. House A, Dennis M, Mogridge L, Warlow C, Hawton K, Jones L. Mood disorders in the year after first stroke. Br J Psychiatry. 1991; 158:83-92.
6. Astrom M, Adolfsson R, Asplund K. Major depression in stroke patients: a 3-year longitudinal study. Stroke. 1993;24:976-982.
7. Parikh RM, Robinson RG, Lipsey JR, Starkstein SE, Federoff JP, Price TR. The impact of post-stroke depression on recovery in activities of daily living over a two-year follow up. Arch Neurol. 1990; 47:785-789.
8. Lipsey JR, Robinson RG, Pearlson GD, Rao K, Price TR. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet. 1984;1:297-300.
9. Reding MJ, Orto LA, Winter SW, Fortuna IM, Di Ponte P, Mc Dowell FH. Antidepressant therapy after stroke: a double-blind trial. Arch Neurol. 1986;43:763-765.
10. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of post-stroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke. 1994;25:1099-1104.
11. Lauritzen L, Bjerg Bendsen B, Vilmar T, Bjerg Bendsen E, Lunde M, Been P. Post-stroke depression: combined treatment with imipramine or desipramine and mianserin: a controlled clinical study. Psychopharmacology. 1994;114:119-122.
12. Hovda DA, Feeney DM. Amphetamine with experience promotes recovery of locomotor function after unilateral frontal cortex injury in the cat. Brain Res. 1984;298:358-361.
13. Sutton RL, Feeney DM. α-Noradrenergic agonists and antagonists affect recovery and maintenance of beam-walking ability after sensorimotor cortex ablation in the rat. Restor Neural Neurosci. 1992; 4:1-11.
14. Kline AE, Chen MJ, Tso-Olivas DY, Feeney DM. Methylphenidate treatment following ablation-induced hemiplegia in rat: experience during drug action alters effects on recovery of function. Pharmacol Biochem Behav. 1994;48:773-779.
15. Boyeson MG, Harmon RL, Jones JL. Comparative effects of fluoxetine, amitriptyline and serotonin on functional motor recovery after sensorimotor cortex injury. Am J Phys Med Rehabil. 1994;73:76-83.
16. Barker EL, Blakely RD. Norepinephrine and serotonin transporters: molecular targets of antidepressant drugs. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press Publishers; 1995:321-333.
17. Richelson E. Cholinergic transduction. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press Publishers; 1995:125-134.
18. Brotman AW, Falk WE, Gelemberg AJ. Pharmacologic treatment of acute depressive subtypes. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press Publishers; 1987:1031-1040.
19. Goldstein LB. Pharmacology of recovery after stroke. Stroke. 1990; 21(suppl III):III-139-III-142.
20. Bobath B. Adult Hemiplegia: Evaluation and Treatment. London, UK: William and Heinnemann; 1978.
21. Adams RJ, Meador KJ, Sethi KD, Grotta JC, Thomson DS. Graded neurologic scale for use in acute hemispheric stroke treatment protocols. Stroke. 1990;71:876-880.
22. Mahoney FI, Barthel DW. Functional evaluation: Barthel Index. Md State Med J. 1965;14:61-65.
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:58-62.
24. Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand. 1986;73(suppl 326):7-37.
25. Freeman R, Bear D, Greenberg MS. Behavioral disturbances in cerebrovascular disease. In: Vinken PJ, Bruyn GW, Klawans HL, Toole JF, eds. Handbook of Clinical Neurology, Vol II (55): Vascular Diseases, Part III. Amsterdam, Netherlands: Elsevier Science Publishers BV; 1989:137-150.
26. Finklestein S, Benowitz LI, Baldessarini RJ, Arana JW, Levine D, Woo E, Bear D, Moya K, Stoll AL. Mood, vegetative disturbance, and dexamethasone suppression test after stroke. Ann Neurol. 1982; 12:463-468.
27. Blackwell B. Newer antidepressant drugs. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress, New York, NY: Raven Press Publishers; 1987:1041-1049.
28. Wood AJJ. Fluoxetine. N Engl J Med. 1994;331:1354-1361.
29. Prasher VP. Seizures associated with fluoxetine therapy. Seizure. 1993;2:315-317.
30. Mayo NE, Korner-Bitensky NA, Becker R. Recovery time of independent function after stroke. Am J Phys Med Rehabil. 1991;70:5-12.
31. Johnston MV, Kirshblum S, Zorowitz R, Shiflett SC. Prediction of outcomes following rehabilitation of stroke patients. Neurorehabil. 1992;2:72-97.
32. Dam M, Tonin P, Casson S, Ermani M, Pizzolato G, Iaia V, Battistin L. The effects of long-term rehabilitation therapy on post-stroke hemiplegic patients. Stroke. 1993;24:1186-1191.
33. Rutter JJ, Gundlha C, Auerbach S. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Lett. 1994;171:183-186.
34. Glanzman DL. Postsynaptic regulation of the development and long term plasticity of aplysia sensorimotor synapses in cell culture. J Neurobiol. 1994;25:666-693.
35. Elliot P, Wallis DI. Serotonin and L-norepinephrine as mediators of altered excitability in neonatal rat motoneurons studied in vitro. Neuroscience. 1992;47:533-544.
36. Mangan PS, Cometa AK, Friesen WO. Modulation of swimming behavior in the medicinal leech, IV: serotonin-induced synaptic alteration of synaptic interactions between neurons of the swim circuit. J Comp Physiol. 1994;175:723-736.
37. Cazalets JR, Sqali-Houssaini Y, Clarac F. Activation of the central pattern generators for locomotion by serotonin and excitatory amino acids in neonatal rat. J Physiol (Lond). 1992;4454:187-204.
38. Bieger D. Role of serotonergic neurotransmission in the initiation of swallowing in the rat. Neuropharmacology. 1981;20:1073-1083.
39. Barbeau H, Rossignol S. Initiation and modulation of the locomotor pattern in the adult chronic spinal cat by noradrenergic, serotonergic and dopaminergic drugs. Brain Res. 1991;546:250-260.
40. Hrdina PD, Vu TB. Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in rat brain: an autoradiographic study. Synapse. 1993;14:324-331.
41. Yamazaki J, Fukuda H, Nagao T, Ono H. 5-HT2/5-HT1C receptor-mediated facilitatory action on unit activity of ventral horn cells in rat spinal cord slices. Eur J Pharmacol. 1992;220:237-242.
42. Palvimaki EP, Laasko A, Kuoppamaki M, Syvalahti E, Hietala J. Up regulation of β1-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatment. Psychopharmacology. 1994;115: 543-546.
43. Nestler EJ, Duman RS. Intracellular messenger pathways as mediator of neural plasticity. In: Bloom FE, Kupfer DJ, eds. Psychopharmacologv: The Fourth Generation of Progress. New York, NY: Raven Press Publishers; 1995:695-704.
44. Clark ANG, Mankikar GD. d-Amphetamine in elderly patients refractory to rehabilitation procedures. J Am Geriatr Soc. 1979;27:174-177.
45. Crisostomo EA, Duncan PW, Propst M, Dawson DV, Davis JN. Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients. Ann Neurol. 1988;23:94-97.